Company Overview
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -3.54% |
| 6 Months: | +40.49% |
| 3 Months: | -4.34% |
| 1 Month: | +5.23% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)57.62 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BHVN Biohaven Ltd. R2KR3KPHARMA | 13.88 | -3.04 | $2.10B | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | - | -55.49M | -89.77M | -197.11M | -67.64M | -77.78M | -94.01M | -110.55M | -183.24M | -333.77M | -178.17M | -221.56M | -211.70M | -169.38M | -130.43M | -124.90M |
| Net Income | -62.12M | -45.42M | -54.37M | -97.03M | -203.29M | -68.85M | -70.49M | -90.35M | -102.57M | -179.50M | -319.77M | -160.30M | -221.68M | -198.15M | -173.44M | -130.53M | -137.31M |
| Diluted EPS | - | - | -1.38 | -2.46 | -5.16 | -1.75 | -1.03 | -1.32 | -1.50 | -2.20 | -3.64 | -1.70 | -2.17 | -1.94 | -1.64 | -0.88 | -0.91 |
| R&D Expense | - | - | 46.97M | 70.10M | 177.09M | 52.84M | 63.46M | 79.49M | 95.52M | 155.97M | 314.82M | 157.61M | 187.58M | 184.37M | 141.17M | 103.83M | 100.81M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 567.93M | 436.05M | 885.11M | 745.38M |
| Operating Income | -114.51M | - | -567.93M | -436.05M | -885.11M | -745.38M |
| EBITDA | - | - | -566.55M | -429.14M | -877.26M | -735.46M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | - | -569.84M | -409.55M | -845.69M | -737.38M |
| Tax Provision | - | - | 438.00K | -1.38M | 735.00K | 1.44M |
| Net Income | -118.67M | - | -570.28M | -408.17M | -846.42M | -738.82M |
| Diluted EPS | -3.01 | - | -12.75 | -5.73 | -9.28 | -6.86 |
| R&D Expense | 98.46M | 181.49M | 437.07M | 373.28M | 795.87M | 635.07M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 661.78M | 513.21M | 615.11M | 451.45M |
| Current Assets | - | - | - | 586.97M | 442.45M | 538.47M | 368.33M |
| Cash & Equivalents | - | 82.51M | - | 204.88M | 248.40M | 99.13M | 229.96M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | 9.91M | 46.14M | 13.25M | 2.60M | - |
| Total Liabilities | - | - | - | 123.01M | 85.24M | 191.67M | 399.38M |
| Current Liabilities | - | - | - | 90.02M | 55.42M | 154.23M | 115.93M |
| Long Term Debt | - | - | - | - | - | - | 238.90M |
| Total Debt | - | - | - | 33.60M | 30.88M | 36.58M | 284.61M |
| Total Equity | 14.45M | 16.78M | - | 538.77M | 427.98M | 423.44M | 52.07M |
| Shares Outstanding | - | - | - | 68.19M | 81.12M | 101.22M | 132.78M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -75.96M | -145.84M | -297.69M | -331.73M | -582.45M | -609.44M |
| Investing Cash Flow | -2.70M | 944.00K | -304.79M | 129.83M | -244.97M | 300.56M |
| Financing Cash Flow | 152.24M | 138.45M | 767.60M | 211.91M | 677.77M | 439.12M |
| Capital Expenditure | -1.10M | -938.00K | -6.07M | -3.05M | -4.05M | -715.00K |
| Free Cash Flow | -77.05M | -146.78M | -303.76M | -334.77M | -586.50M | -610.15M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | -707.2% | - | -105.8% | -95.4% | -199.9% | -1,418.8% |
| ROCE % | - | - | -99.3% | -95.3% | -192.0% | -222.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.75% | 13.21M | $159.58M |
| 2 | Montanova Capital LLC | 6.81% | 10.29M | $124.27M |
| 3 | Stifel Financial Corporation | 6.58% | 9.94M | $120.09M |
| 4 | Jupiter Topco LLC | 5.68% | 8.58M | $103.70M |
| 5 | Woodline Partners LP | 5.07% | 7.66M | $92.54M |
| 6 | State Street Corporation | 4.60% | 6.95M | $83.92M |
| 7 | Infinitum Asset Management, LLC | 4.14% | 6.25M | $75.50M |
| 8 | Shaw D.E. & Co., Inc. | 2.77% | 4.19M | $50.62M |
| 9 | AQR Capital Management, LLC | 2.75% | 4.15M | $50.14M |
| 10 | Geode Capital Management, LLC | 2.20% | 3.32M | $40.14M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BHVN
Biohaven Ltd. (BHVN) stock price, news, quote and history - Yahoo Finance Australia
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTFBFX0d6VWM1ZVNkZ3ZYVV91cTdhU3NXMy1GX3NwSEFQWVgzbUNlSWlyQUppYVU5dk5YeTV5Z3ZobVZ1RFpNbUFzSzJtN1RIdXA1TFE?oc=5" target="_blank">Biohaven Ltd. (BHVN) stock price, news, quote and histor…
Why Is BHVN Stock Falling Premarket? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQMGVxbjdtaENTWDdXRFlwXzJmRTV6TFYzcVpMVC1tQVk5TWhvaExDRlh2alF0bEg4LXlNVEw2VFo1STNobFQtcktfdHBiZ2M4RFduc3RFMjNSemlveG5ReTRfZnFnNF9OZXRQM3hsb1VOeTJOaVQ0UWpPangwNW5zQU1FQXI0MVpoLWZVaE…
Why Biohaven's 25% Surge Might Be Just The Beginning - Investor's Business Daily
<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxOX3RVRlNTeDlDR28wZlhNcUhRWFpCUV9JSVJ2eG5XOGp2VVM0YTktNGNaYWliVzcteWVpN0oyek1jMnMtZGViY183blNjT2w4QndOQjlQRXJ4LURtRDhqaUtBejlmWG9ZU1h3SEp3b2U4N0ZQeThvcy1JWHpQZHhmckVfZw?oc=5" targe…
Biohaven Stock Soars As FDA Accepts Vyglyxia Resubmission - This Plot Is Too Thick For Me - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxQcks1OGNpWlVQRTRSazFYN3V1YXdXZXNjd1prV1F5Tl84MWhSQWpVbmVOMzMxY2dhZHZUeEVrczVNaUZSWVZFdHpNMjFKenpiTkRza1B1cFM5b1Vic3M5RlJCWEJfNnBfamNfZl9hdzQ4Q2xfWDhESUlYVFdoOHJ4SElpZFlHR1NVZE1YNV…
Biohaven (BHVN) Soars 25% on FDA Drug Review, Price Target Upgrade - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxNbnhCSm9OempxMTNNYzJWZzFmRWVVOUtFWnBKczMxMkVXOWluMEQtbEdTU1V5U201RUROVUppbWVHU0J3RnN0RVBoclFtLVF1bmM2cG1Pb043d05NMVdDWmhnM1NZMFhDeTZWbWJCNTlhNEx4Z21zY1p5QXpfS1BiSGR2YUxoR25VYldSb0…
Does FDA Review Acceptance Change The Bull Case For Biohaven Stock (BHVN)? - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxNaEx0cGN0NUIyWXJpajRGak12Q204eG5zcHA3TkViYXFaS0JadVZNVzFfTGdhS3F0WTd2U01hcXZXb2tkd05OWEtlT3h1VEQ0UVdoUWJ1QzdiUXFOXzRkWGNvYnNkNWhfT3ZBdHZhTTJGODdqNTczQ3B4YnNfRTVVckZzZ1BMaEZ0d0xxRn…
BHVN — Frequently Asked Questions
What is the current share price of Biohaven Ltd. (BHVN)?
As of 2026-10-23 16:27 PDT, Biohaven Ltd. (BHVN) trades at $13.88 on NYSE. Its 52-week range is $7.79 to $18.11.
What is the market capitalisation of BHVN?
Biohaven Ltd. (BHVN) has a market capitalisation of $2.10B on NYSE.
What is the P/E ratio of BHVN?
BHVN trades at a trailing price-to-earnings (P/E) ratio of -3.04. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 149.14.
Is BHVN a good stock to buy?
This page provides a data-driven analysis of Biohaven Ltd. (BHVN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.